Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 196

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 196
---
Proposal requires the affirmative vote, in person or by proxy, of the majority of the voting power of the shares present in person or represented by proxy at the meeting and entitled to vote on the subject matter. You may vote “FOR,”
“AGAINST” or “ABSTAIN.” Broker non-votes, if any, will not be counted as entitled to vote on the subject matter for this proposal and accordingly, will have no effect on the outcome of the PIPE Financing Proposal, and abstentions
will be counted in the same manner as votes “AGAINST” the PIPE Financing Proposal.

THE AADI BOARD OF DIRECTORS RECOMMENDS A VOTE “FOR” PROPOSAL NO. 2. THE PIPE FINANCING PROPOSAL

- 133 -

PROPOSAL NO. 3:

APPROVAL OF THE EQUITY PLAN INCREASE PROPOSAL

THE AADI BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT AADI STOCKHOLDERS VOTE “FOR” THE EQUITY PLAN INCREASE.

Overview

We are asking our stockholders to approve the
amendment and restatement of our 2021 Plan (as amended and restated, the “Amended and Restated Plan”) to (i) increase the number of shares available for future grant under the 2021 Plan from 2,000,284 shares to 8,300,284 shares
and (ii) increase the 2021 Plan’s default annual automatic share reserve increase occurring on January 1 of each year from 4% of outstanding shares on the last day of the immediately preceding fiscal year to 5% (the “Equity Plan
Increase”). Our board of directors has approved the Equity Plan Increase, subject to approval from stockholders. We are asking our stockholders to approve the Equity Plan Increase because we are transitioning our business model from being a
commercial business to being a drug development business, and we have insufficient shares available to continue to make equity grants, which we believe are necessary to be able to recruit new employees and continue to provide long-term incentives to
existing employees and directors. Outstanding awards will remain outstanding and shall continue to be subject to the terms of the 2021 Plan and the respective award agreements, until the expiration of such awards in accordance with their terms.

The Equity Plan Increase includes increasing the number of shares available for future grant under the Amended and Restated Plan by 6,300,000 shares and
increasing the default annual automatic share